Imiquimod cream

Imiquimod can induce a variety of cytokines and related products at the local site of medication, thereby producing immunomodulatory and indirect antiviral effects. Imiquimod can effectively induce a variety of cytokines including alpha-interferon (IFN-alpha) and alpha-tumor necrosis factor (TNF-alpha) both in vivo and in vitro. In vitro, it can induce human peripheral blood mononuclear cells to produce the following cytokines: alpha-interferon (IFN-alpha), alpha-tumor necrosis factor (TNF-alpha), interleukins (IL-1alpha, IL-1beta, IL-6, 8, 10), colony stimulating factors (C-CSF, GM-CSF) and chemotactic cytokines (MCP-1alpha, MCP-1beta), etc. The concentrations of IFN-alpha and TNF-alpha in the skin reached a peak one hour after topical application of imiquimod cream (0.05mu;g/cm2). The two metabolites of imiquimod, S-26704 and S-22770, have similar immunological activity. The maximum concentration of imiquimod cream is 18.3%. When administered at 1.0 g/kg, a local skin toxicity test on rabbits was conducted. After continuous administration for one week, no obvious skin irritation was observed except for slight erythema formation. No sensitization effect on guinea pig skin was found. This product has no carcinogenic, mutagenic or teratogenic toxicity. Skin tolerance tests show that imiquimod is non-irritating to normal human skin.

The main ingredient of this product is imiquimod.

This product is a white or off-white cream with an emulsion base.

Genital and perianal condyloma acuminatum in adults.

1. Take the medicine before going to bed 3 times a week (Monday, Wednesday, Friday or Tuesday, Thursday, Saturday). Use the medicine rationally under the guidance of a doctor to maximize the efficacy of this product. It is recommended to wash your hands before and after taking the medicine. Imiquimod cream is packaged in single or multiple doses. Each pack of cream (or 250mg cream) can be applied to a wart with an area of 20cm2. Avoid excessive use of this product. 2. Take an appropriate amount of ointment before going to bed, apply a thin layer evenly on the wart area, gently massage until the medicine is completely absorbed, and keep it for 6-10 hours. Do not seal the medication area. 3. Do not take a bath 6-10 hours after applying the ointment; after 6-10 hours, wash the medicine off the wart area with clean water and neutral soap. 4. Patients should continue to use the ointment until the wart is completely cleared; the wart is cleared in 2-4 weeks at the fastest, usually in 8-12 weeks, and the medication should not exceed 16 weeks. 5. If mild erythema occurs locally after taking the medicine, it is not necessary to stop the medicine and continue to use it: If the patient feels general discomfort or has more obvious local skin reactions (such as more obvious edema, erosion, pain, etc.), the medicine should be stopped several times and then continued after the reaction is alleviated.

Most patients do not have any adverse reactions during the treatment. After several doses of medication, the adverse reactions that may occur clinically are mostly mild to moderate local skin inflammatory reactions, such as erythema, edema, erosion, ulcer, desquamation, burning, pain, itching, etc.; occasionally there is a short low fever, and the above symptoms can be quickly eliminated after stopping the medication. If the reaction is mild, you can continue to take the medication; if the reaction is serious, you should stop taking the medication in time and seek medical attention. According to foreign data reports, more than 1% of patients may experience adverse reactions that may be related to imiquimod cream, including: discomfort at the medication site: reactions at the wart site (burning, pigmentation, inflammation, itching, pain, rash, sensitivity, ulcer, tingling, tenderness); reactions around the wart (bleeding, burning, itching, pain, tenderness); systemic reactions: fatigue, fever, flu-like symptoms; discomfort in the central and peripheral nervous systems: headache; discomfort in the gastrointestinal system: diarrhea; discomfort in the musculoskeletal system: myalgia.

Not yet known.

Precautions for children: The safety and efficacy of this product in patients under 18 years of age have not been established. Precautions for pregnancy and lactation: 1. This product is not recommended for pregnant women. 2. It is not known whether the drug is secreted in breast milk after topical application of imiquimod. This product is not recommended for lactating women. Precautions for the elderly: The safety and efficacy data of this product for elderly patients have not been established.

Not clear yet.

Keep away from light, store in a sealed container at 25°C, do not freeze.

2g:0.1g

24 months.

YANGTZE River Pharmaceutical Group Jiangsu JOINT STOCK Co., Ltd.

• Founded in:

  1994-07-28

• Address:

  No. 2 Tongjiang East Road, Gaogang District, Taizhou City, Jiangsu Province

• Tax NO.:

  91321200703973749K

• Registered Funds:

  202.679 million yuan

• Website:

  Log in to view

• Email:

  Log in to view